Clinical Implications Beyond Diabetes and Obesity While retatrutide is being tested primarily for obesity and type 2 diabetes , its impact on LDL suggests future use in: Cardiovascular disease prevention (alongside statins or in statin-intolerant patients) Metabolic syndrome management Nonalcoholic fatty liver disease (NAFLD/NASH) , since LDL and triglyceride metabolism are central to liver health Complementary to Statins Unlike statins, which only reduce LDL synthesis, retatrutide may work through multiple lipid pathways , making it synergistic rather than redundant
But, quite a few other cell types, can and do, make carnosine, including the kidneys, where the carnosine is nephro-protective
Eating fiber-rich foods, lean proteins, and fermented foods may help boost natural GLP-1 release
Table 1: Mean HbA1c and weight changes in patients with T2D treated with semaglutide and tirzepatide Table 2: Weight loss in patients with obesity (without T2D) treated with semaglutide and tirzepatide Figure 1: Pleiotropic effects of dual GIP/GLP-1 RA Influence of social media (over doctors'!) Semaglutide's skyrocketing popularity has been fuelled by social media
Lost 28 lbs "After struggling with weight loss, I discovered Willow and highly recommend it." Chelsea D